EUVIMEDEUVIMED entdecken
Crossref

Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout

Yuchi He, Liangkaobei Chen, Jialong Jia, Yifan Liu, Yuqing Chen, Xiyu Zhang, Ya Liu

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04641-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Yuchi He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Ramipril, Lisinopril, Benzimidazoles, Hypertension. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension frequently coexists with gout, and previous studies have suggested a potential association between these conditions. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are essential treatments for hypertension, though their effects on gout risk remains unclear and contradictory. We employed data from the FDA Adverse Event Reporting System (FAERS) alongside two-sample and multivariable Mendelian randomization (MR) analysis to evaluate the independent effects of hypertension, candesartan, lisinopril, and ramipril on gout risk. Analysis of FAERS data revealed that the lower bound of the 95% CI for ROR exceeded 1 for candesartan, lisinopril, and ramipril, suggesting potential associations with gout. However, two-sample MR analysis indicated significant causal links only for ramipril and hypertension. And in multivariable MR analysis, the association remained significant solely for hypertension. In summary, our study identifies a significant causal relationship between hypertension and gout risk but does not support a causal effect for the three antihypertensive medications-candesartan cilexetil, lisinopril, and ramipril.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RamiprilLisinoprilBenzimidazolesHypertensionTetrazolesAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsGoutHumansBiphenyl CompoundsMendelian Randomization Analysis

Stichwörter der Autor:innen

Adverse drug eventsAngiotensin II receptor blockersAngiotensin converting enzyme inhibitorsGoutHypertensionMendelian randomization

Substanzen

RamiprilLisinoprilBenzimidazolesTetrazolesAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsBiphenyl Compoundscandesartan

Autor:innen und Institutionen

  • Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. liuyaya918@163.com.

Förderung

  • Science and Technology Department of Sichuan Province

Zitieren

APA

He, Y., Chen, L., Jia, J., Liu, Y., Chen, Y., Zhang, X., & Liu, Y. (2026). Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04641-7

Vancouver

He Y, Chen L, Jia J, Liu Y, Chen Y, Zhang X, et al. Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04641-7

BibTeX
@article{He2026,
  author = {He, Yuchi and Chen, Liangkaobei and Jia, Jialong and Liu, Yifan and Chen, Yuqing and Zhang, Xiyu and Liu, Ya},
  title = {Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04641-7}
}
Kostenlos starten →